Dynamic Technology Lab Private Ltd Invests $1.69 Million in Medtronic PLC $MDT

Dynamic Technology Lab Private Ltd acquired a new position in shares of Medtronic PLC (NYSE:MDT) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,794 shares of the medical technology company’s stock, valued at approximately $1,689,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its position in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 37,265 shares during the last quarter. CoreCap Advisors LLC boosted its position in Medtronic by 16.8% during the 4th quarter. CoreCap Advisors LLC now owns 2,244 shares of the medical technology company’s stock worth $179,000 after acquiring an additional 322 shares during the last quarter. Forefront Analytics LLC grew its stake in shares of Medtronic by 32.5% during the 4th quarter. Forefront Analytics LLC now owns 3,077 shares of the medical technology company’s stock worth $246,000 after acquiring an additional 754 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Medtronic by 100.2% in the fourth quarter. Focus Partners Wealth now owns 199,003 shares of the medical technology company’s stock valued at $16,345,000 after purchasing an additional 99,587 shares during the last quarter. Finally, Graham Capital Management L.P. bought a new stake in shares of Medtronic in the fourth quarter worth $1,322,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on MDT shares. Leerink Partnrs raised shares of Medtronic to a “strong-buy” rating in a research report on Monday, June 16th. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, August 30th. BTIG Research restated a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a report on Thursday, August 14th. Finally, Wells Fargo & Company increased their price target on Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.14.

Medtronic Price Performance

NYSE:MDT opened at $92.93 on Friday. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $96.25. The firm has a market capitalization of $119.20 billion, a price-to-earnings ratio of 25.60, a P/E/G ratio of 2.36 and a beta of 0.77. The stock’s 50 day moving average price is $90.97 and its two-hundred day moving average price is $88.14. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same period in the previous year, the firm earned $1.23 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Stockholders of record on Friday, September 26th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

Insider Activity

In related news, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.